Hitachi PROBEAT-V
Modality: Proton Therapy
Hitachi's flagship multi-room proton-therapy platform — synchrotron-based accelerator with pencil-beam-scanning delivery, deployed across U.S. and international academic proton-therapy centers. Direct competitor to IBA Proteus PLUS in the multi-room category. The Hitachi platform that anchors several of the largest proton-therapy programs globally (MD Anderson, Mayo Clinic, MGH, others).
Distinctive technology
- Synchrotron accelerator — energy variation per pulse without absorbers; clinical-workflow advantage over cyclotron competitors.
- Pencil-beam scanning (PBS) — modern clinical standard.
- 3–5 treatment rooms per synchrotron — capital-intensity optimization for high-volume academic sites.
- Image-guided proton therapy (IGPT) — kV CBCT and stereoscopic-X-ray patient-positioning verification.
- Real-time motion management — gating and breath-hold integration for moving targets.
Clinical use
- Pediatric oncology — CNS tumors, sarcomas, retinoblastoma; dose-sparing for growing patients.
- Base-of-skull / CNS — chordoma, chondrosarcoma, optic-pathway tumors.
- Selected adult indications — base-of-skull, re-irradiation, eye / orbit, AYA cancers.
- Hadron-therapy research — academic centers running proton-therapy clinical trials.
Refurb posture
- No meaningful refurb market — proton-therapy installed base is small and per-vendor.
- Service-contract continuity dominates operating economics.
- Multi-decade lifecycle — proton-therapy synchrotrons run for decades with periodic upgrades.